AIMS: To examine the effect of β-adrenoceptor blocker treatment on cancer survival. METHODS: In a UK primary care database, we compared patients with a new cancer diagnosis receiving β-adrenoceptor blockers regularly (n= 1406) with patients receiving other antihypertensive medication (n= 2056). RESULTS: Compared with cancer patients receiving other antihypertensive medication, patients receiving β-adrenoceptor blocker therapy experienced slightly poorer survival (HR = 1.18, 95% CI 1.04, 1.33 for all β-adrenoceptor blockers; HR = 1.21, 95% CI 0.94, 1.55 for non-selective β-adrenoceptor blockers). This poorer overall survival was explained by patients with pancreatic and prostate cancer with no evidence of an effect on survival for patients with lung, breast or colorectal cancer. Analysis in a cancer-free matched parallel cohort did not suggest selection bias masked a beneficial effect. CONCLUSION: Our study does not support the hypothesis that β-adrenoceptor blockers improve survival for common cancers.
AIMS: To examine the effect of β-adrenoceptor blocker treatment on cancer survival. METHODS: In a UK primary care database, we compared patients with a new cancer diagnosis receiving β-adrenoceptor blockers regularly (n= 1406) with patients receiving other antihypertensive medication (n= 2056). RESULTS: Compared with cancerpatients receiving other antihypertensive medication, patients receiving β-adrenoceptor blocker therapy experienced slightly poorer survival (HR = 1.18, 95% CI 1.04, 1.33 for all β-adrenoceptor blockers; HR = 1.21, 95% CI 0.94, 1.55 for non-selective β-adrenoceptor blockers). This poorer overall survival was explained by patients with pancreatic and prostate cancer with no evidence of an effect on survival for patients with lung, breast or colorectal cancer. Analysis in a cancer-free matched parallel cohort did not suggest selection bias masked a beneficial effect. CONCLUSION: Our study does not support the hypothesis that β-adrenoceptor blockers improve survival for common cancers.
Authors: Daniel Palm; Kerstin Lang; Bernd Niggemann; Theodore L Drell; Kai Masur; Kurt S Zaenker; Frank Entschladen Journal: Int J Cancer Date: 2006-06-01 Impact factor: 7.396
Authors: Eric V Yang; Seung-jae Kim; Elise L Donovan; Min Chen; Amy C Gross; Jeanette I Webster Marketon; Sanford H Barsky; Ronald Glaser Journal: Brain Behav Immun Date: 2008-10-21 Impact factor: 7.217
Authors: Iain M Carey; Derek G Cook; Stephen De Wilde; Stephen A Bremner; Nicky Richards; Steve Caine; David P Strachan; Sean R Hilton Journal: Int J Med Inform Date: 2004-06-15 Impact factor: 4.046
Authors: Desmond G Powe; Melanie J Voss; Kurt S Zänker; Hany O Habashy; Andrew R Green; Ian O Ellis; Frank Entschladen Journal: Oncotarget Date: 2010-11
Authors: Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Muhammad S Beg; Arjun Gupta; David Sher; Sadia Ali; Saad Khan; Ang Gao; Tyler Stewart; Chul Ahn; Jarett Berry; Eric M Mortensen Journal: Am J Clin Oncol Date: 2018-08 Impact factor: 2.339